Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?
作者信息
Zucker Stanley, Cao Jian
机构信息
Veterans Affairs Medical Center, Northport, NY, USA.
出版信息
Cancer Biol Ther. 2009 Dec;8(24):2371-3. doi: 10.4161/cbt.8.24.10353. Epub 2009 Dec 19.
Abstract
摘要
相似文献
1
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?
Cancer Biol Ther. 2009 Dec;8(24):2371-3. doi: 10.4161/cbt.8.24.10353. Epub 2009 Dec 19.
2
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
Science. 2002 Mar 29;295(5564):2387-92. doi: 10.1126/science.1067100.
3
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
Nat Rev Cancer. 2006 Mar;6(3):227-39. doi: 10.1038/nrc1821.
4
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203. doi: 10.1023/a:1023047431869.
5
Development of matrix metalloproteinase inhibitors in cancer therapy.
J Natl Cancer Inst. 2001 Feb 7;93(3):178-93. doi: 10.1093/jnci/93.3.178.
6
Towards third generation matrix metalloproteinase inhibitors for cancer therapy.
Br J Cancer. 2006 Apr 10;94(7):941-6. doi: 10.1038/sj.bjc.6603043.
7
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Pharmacotherapy. 2002 Jun;22(6):705-20. doi: 10.1592/phco.22.9.705.34062.
8
Matrix metalloproteinases. Novel targets for directed cancer therapy.
Drugs Aging. 1997 Sep;11(3):229-44. doi: 10.2165/00002512-199711030-00006.
9
[Expression of matrix metalloproteinases in patients with malignant tumors].
Medicina (Kaunas). 2004;40(12):1143-50.
10
Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
Expert Opin Drug Discov. 2018 Jan;13(1):75-87. doi: 10.1080/17460441.2018.1398732. Epub 2017 Oct 31.
引用本文的文献
1
Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies.
Biochemistry. 2020 Oct 13;59(40):3802-3812. doi: 10.1021/acs.biochem.0c00690. Epub 2020 Sep 30.
2
Recent insights into natural product inhibitors of matrix metalloproteinases.
Medchemcomm. 2019 Oct 7;10(12):2024-2037. doi: 10.1039/c9md00165d. eCollection 2019 Dec 1.
3
Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
Front Immunol. 2019 Jun 4;10:1278. doi: 10.3389/fimmu.2019.01278. eCollection 2019.
4
Evaluation of MMP Inhibitors Isolated from Fructus.
Molecules. 2019 Feb 8;24(3):604. doi: 10.3390/molecules24030604.
5
Reducing proteolytic liability of a MMP-14 inhibitory antibody by site-saturation mutagenesis.
Protein Sci. 2019 Mar;28(3):643-653. doi: 10.1002/pro.3567. Epub 2019 Jan 11.
6
Use of a novel camelid-inspired human antibody demonstrates the importance of MMP-14 to cancer stem cell function in the metastatic process.
Oncotarget. 2018 Jun 29;9(50):29431-29444. doi: 10.18632/oncotarget.25654.
7
Generation of Highly Selective MMP Antibody Inhibitors.
Methods Mol Biol. 2018;1731:307-324. doi: 10.1007/978-1-4939-7595-2_26.
8
Synthesis and Evaluation of New Oxadiazole, Thiadiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9.
Molecules. 2017 Jul 4;22(7):1109. doi: 10.3390/molecules22071109.
9
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.
J Control Release. 2017 Aug 10;259:62-75. doi: 10.1016/j.jconrel.2017.01.034. Epub 2017 Jan 31.
10
Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.
Biotechnol Bioeng. 2017 Jun;114(6):1140-1150. doi: 10.1002/bit.26248. Epub 2017 Feb 20.
本文引用的文献
1
A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth.
Cancer Biol Ther. 2009 Dec;8(24):2362-70. doi: 10.4161/cbt.8.24.10139. Epub 2009 Dec 19.
2
A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis.
Mol Cell Biol. 2009 Jul;29(13):3722-37. doi: 10.1128/MCB.01164-08. Epub 2009 May 4.
3
Optical proteolytic beacons for in vivo detection of matrix metalloproteinase activity.
Methods Mol Biol. 2009;539:155-74. doi: 10.1007/978-1-60327-003-8_9.
4
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.
Cancer Res. 2009 Feb 15;69(4):1517-26. doi: 10.1158/0008-5472.CAN-08-3255. Epub 2009 Feb 10.
5
Rac activation and inactivation control plasticity of tumor cell movement.
Cell. 2008 Oct 31;135(3):510-23. doi: 10.1016/j.cell.2008.09.043.
6
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
J Clin Oncol. 2006 Jun 20;24(18):2786-92. doi: 10.1200/JCO.2005.04.1764.
7
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
Nat Rev Cancer. 2006 Mar;6(3):227-39. doi: 10.1038/nrc1821.
8
MT1-MMP: a potent modifier of pericellular microenvironment.
J Cell Physiol. 2006 Jan;206(1):1-8. doi: 10.1002/jcp.20431.
9
A bioinorganic perspective on matrix metalloproteinase inhibition.
Curr Top Med Chem. 2004;4(15):1551-73. doi: 10.2174/1568026043387368.
10
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
J Clin Oncol. 2004 Dec 1;22(23):4683-90. doi: 10.1200/JCO.2004.08.054.
Zotero 插件